Major depressive disorder is far more than a mood condition. Beyond low mood and lost interest, many patients struggle with memory, attention, and executive function—deficits that often persist between depressive episodes and interfere with work, relationships, and daily life. At the same time, researchers have long noted that depression travels with metabolic disturbances such as insulin resistance, and with elevated levels of inflammatory molecules circulating in the blood. What has remained murky is how these threads connect to one another, and why some patients develop cognitive problems while others do not.

The research team, led by investigators at Xiamen Xianyue Hospital affiliated with Xiamen Medical College, recruited 300 people with major depressive disorder—100 men, 100 premenopausal women, and 100 postmenopausal women—along with 150 age- and body mass index-matched healthy controls. Participants were assessed between February 2021 and September 2024 using a battery of measures designed to capture the full biological and clinical picture: the triglyceride-glucose index, a simple calculated marker of insulin resistance; serum neuropeptide Y measured by enzyme-linked immunosorbent assay; inflammatory markers including interleukin-6, tumor necrosis factor-alpha, and C-reactive protein; appetite ratings on a visual analog scale; depression severity on the 17-item Hamilton Depression Rating Scale; and cognition using the Montreal Cognitive Assessment.

The results were striking from the first comparison. Patients with depression showed significantly higher triglyceride-glucose index values, higher neuropeptide Y levels, and greater inflammation than controls, alongside markedly lower cognitive scores. Neuropeptide Y, a peptide released during stress that also regulates appetite and energy balance, was elevated most prominently in premenopausal women—a detail that immediately signaled the importance of sex and reproductive status in the underlying biology.

Correlation analyses deepened the picture. Neuropeptide Y tracked positively with both the triglyceride-glucose index and appetite ratings, with correlation coefficients ranging from 0.43 to 0.52, suggesting that as metabolic dysfunction worsened, the peptide rose in tandem with increased appetite. But the same molecule told a darker story about the brain: it correlated negatively with cognitive performance, with coefficients between −0.35 and −0.46. The stronger a patient’s metabolic derangement and appetite disturbance, the worse their performance on tests of memory and thinking—and once again, these relationships were strongest in premenopausal women.

To test whether neuropeptide Y actually serves as a conduit between metabolism and cognition, the team used a statistical technique called moderated mediation analysis. The findings revealed a layered pathway. Inflammation partially mediated the link between neuropeptide Y and cognitive scores, accounting for roughly 39 percent of the total effect. In other words, high neuropeptide Y appears to fuel inflammatory processes, and those inflammatory signals in turn chip away at cognitive function.

The full chain ran even further back. Neuropeptide Y and inflammation jointly mediated the relationship between the triglyceride-glucose index and cognition, with the joint indirect effect explaining 36.88 percent of the total association. Critically, this mediation was moderated by sex and reproductive status: the pathway was most powerful in premenopausal women, where the indirect effect accounted for 42.37 percent of the total—meaning that in younger women, nearly half of the connection between poor metabolic health and cognitive impairment flows through elevated neuropeptide Y and inflammation.

The authors suggest several mechanisms that could underlie these sex differences. Neuropeptide Y levels are known to vary with estrogen status, and estrogen interacts with both metabolic regulation and immune signaling. Premenopausal women, with higher circulating estrogen, may mount a distinct metabolic and inflammatory response to depression—one in which appetite changes driven by neuropeptide Y are more pronounced, and in which the downstream inflammatory consequences for the brain are amplified. After menopause, this coupling appears to loosen, producing a different risk architecture.

Beyond clarifying mechanism, the study carries immediate clinical promise in the form of a diagnostic tool. The researchers combined four blood measures—the triglyceride-glucose index, neuropeptide Y, interleukin-6, and tumor necrosis factor-alpha—into an integrated biomarker panel and tested its ability to distinguish patients with cognitive impairment using receiver operating characteristic analysis. The panel achieved an area under the curve of 0.869, substantially outperforming the triglyceride-glucose index alone, which managed 0.748. The difference was statistically robust. A simple blood draw, in other words, could one day flag which patients with depression are most at risk of the cognitive dimension of the illness.

The authors caution that the cross-sectional design captures only a snapshot, so cause and effect cannot be definitively established, and longitudinal studies are warranted to confirm whether correcting metabolic dysfunction early can prevent cognitive decline. Still, the implications are considerable. If the pathway holds, interventions targeting insulin sensitivity, neuropeptide Y signaling, or inflammation—tailored to a patient’s sex and reproductive stage—could offer a biological handle on the cognitive symptoms that make depression so disabling. The study is also a reminder that psychiatric illness is embodied: mood, metabolism, immunity, and hormones are not separate stories but a single, sex-specific web, and untangling it may finally explain why the brain falters when the body’s chemistry goes awry.

Neuropeptide Y itself has a long research history that helps explain why it sits at the center of this pathway. It is one of the most abundant neuropeptides in the mammalian nervous system, co-released with norepinephrine during stress, where it classically acts to buffer the cardiovascular and emotional impact of acute stressors. Yet the same peptide is also a potent orexigenic signal, stimulating food intake and promoting fat storage when released in hypothalamic circuits. This dual identity—stress resilience on one hand, metabolic promotion on the other—may account for the seemingly paradoxical findings in the new study, in which higher neuropeptide Y accompanied greater appetite but poorer cognition. Chronic elevation of a peptide designed for short-term stress responses may carry costs that only become apparent over time, particularly in metabolic and immune systems.

The choice of the triglyceride-glucose index as the study’s metabolic anchor reflects broader trends in cardiometabolic research. Unlike direct measures of insulin resistance, which require fasting insulin assays or dynamic testing, the index is computed from routine fasting triglyceride and glucose values, making it inexpensive and easy to deploy in large cohorts and clinical settings. It has been validated across numerous populations as a surrogate for insulin resistance and has repeatedly been associated with adverse outcomes ranging from cardiovascular disease to non-alcoholic fatty liver disease. Its appearance here as a predictor of cognitive impairment in depression extends that literature into psychiatry, and its practicality matters: a marker that requires only a standard metabolic panel could be incorporated into routine psychiatric care far more readily than specialized testing.

The inflammatory markers used in the study likewise represent well-characterized players in the biology of depression. Interleukin-6 and tumor necrosis factor-alpha are pro-inflammatory cytokines that can signal to the brain through both humoral and neural routes, influencing neurotransmitter metabolism, hypothalamic-pituitary-adrenal axis activity, and neuroplasticity. Elevated peripheral inflammation has been reported in subsets of depressed patients for decades, and previous work has linked inflammatory activity to specific symptom dimensions, including fatigue, psychomotor slowing, and cognitive difficulties. The present findings sit comfortably within that tradition while adding a mechanistic twist: inflammation appears not simply as a correlate of depression but as a downstream conduit through which metabolic and neuropeptide signals reach the brain.

The statistical architecture of the study also deserves note. Moderated mediation analysis allows researchers to test both an indirect pathway—whether one variable transmits the effect of another—and whether that transmission differs across subgroups. By applying this framework separately to men, premenopausal women, and postmenopausal women, the investigators could quantify how the same biological chain varies in strength depending on hormonal context. The confidence intervals reported for the indirect effects excluded zero across the full sample and in the premenopausal subgroup, lending statistical weight to conclusions that might otherwise rest on visual inspection of subgroup differences alone.

The diagnostic analysis likewise illustrates methodological principles worth understanding. The area under the receiver operating characteristic curve expresses, on a scale from 0.5 to 1.0, how well a marker separates affected from unaffected individuals, with values above 0.8 generally considered useful discrimination. The jump from 0.748 for the triglyceride-glucose index alone to 0.869 for the four-marker panel, confirmed by a formal comparison test, demonstrates the additive value of measuring multiple biological dimensions rather than any single one. This multibiomarker approach mirrors strategies already standard in cardiovascular risk assessment, where combinations of lipid, inflammatory, and metabolic measures outperform any lone indicator.

Finally, the study’s framing around reproductive stage rather than sex alone points toward a more nuanced future for psychiatric biomarker research. Menopause represents a natural experiment in estrogen withdrawal, and the loosening of the neuropeptide Y–inflammation–cognition coupling observed after menopause suggests that ovarian hormones actively shape how metabolic stress is translated into neural injury. Disentangling these hormonal contributions may ultimately identify which patients benefit most from metabolic or anti-inflammatory interventions, moving psychiatry closer to biologically stratified treatment.

Subject of Research: How neuropeptide Y connects metabolic dysfunction and inflammation to cognitive impairment in major depressive disorder across sex and menopausal status.

Article Title: Interplay of neuropeptide Y, metabolic dysfunction, and inflammation in cognitive impairment of major depressive disorder: a sex-stratified study

Article References: Yuan, Q., Elhassan, M. A. M., Zhang, H., Wang, L., Zhu, X., Wu, Z., Lin, D., & Huang, Z. (2026). Interplay of neuropeptide Y, metabolic dysfunction, and inflammation in cognitive impairment of major depressive disorder: a sex-stratified study. Biology of Sex Differences. https://doi.org/10.1186/s13293-026-00981-y

Image Credits: AI Generated

DOI: 10.1186/s13293-026-00981-y

Keywords: major depressive disorder, neuropeptide Y, cognitive impairment, triglyceride-glucose index, inflammation, insulin resistance, sex differences, menopause, biomarkers, interleukin-6, IL-6, MoCA

Major depressive disorder remains a formidable global health challenge, characterized not only by its pervasive depressive symptoms but also by the heightened risk of suicide it engenders. Suicide stands as one of the most devastating and yet unpredictable outcomes of MDD, underscoring the urgent necessity for reliable biomarkers that can facilitate early and precise risk stratification. The new findings reflect an evolution from traditional psychological assessments towards biochemical diagnostics, aiming to fill critical gaps in the prediction and prevention of suicidal behavior.

The study harnessed the power of electronic health records from Beijing Anding Hospital, encompassing a robust cohort of 1,115 MDD patients over an eight-year span. Employing sophisticated propensity score matching techniques, researchers meticulously paired 483 patients who exhibited suicidal ideation or behaviors with an equal number of non-suicidal counterparts. This methodological rigor ensured that confounding variables were minimized, allowing for a clearer examination of the associations between specific serum biomarkers and suicide risk.

Serum folate emerged as a particularly potent factor inversely associated with the risk of suicide. Elevated folate levels, defined as greater than 6 ng/mL, significantly correlated with decreased likelihood of suicidal ideation or attempts, with odds ratios indicating a strong protective effect. Intriguingly, this relationship was markedly pronounced in male patients, suggesting potential sex-specific biological pathways that mediate depressive psychopathology and suicidality. The ramifications of folate’s role extend into neurochemical domains, implicating it in neurotransmitter synthesis and function.

Equally compelling was the relationship identified between homocysteine (HCY) levels and suicide risk, especially within the demographic of patients aged 45 years or younger. Contrary to expectations, lower homocysteine concentrations (at or below 11.1 µmol/L) were associated with increased suicide risk in this subgroup. Homocysteine, often discussed in cardiovascular and neurodegenerative contexts, appears to assume a complex role within psychiatric frameworks, potentially reflecting altered methylation processes integral to brain function and mood regulation.

The research also evaluated other biochemical indicators, including C-reactive protein (CRP), adrenocorticotropic hormone (ACTH), and testosterone, none of which demonstrated a significant association with suicidality in this patient population. These negative findings are illuminating, as they delineate the biochemical landscape of suicide risk and highlight the unique relevance of folate and homocysteine among a plethora of candidate biomarkers.

The clinical and neurobiological implications of these findings are manifold. Folate is essential for one-carbon metabolism, facilitating crucial methylation reactions involved in epigenetic regulation and neurotransmitter synthesis such as serotonin, dopamine, and norepinephrine. Its deficiency has long been linked to depressive symptomatology, but its specific relationship to suicidality now garners empirical support. Conversely, the paradoxical association of lower homocysteine with increased risk challenges conventional assumptions and calls for deeper mechanistic studies to decode its role in neural plasticity and stress response.

This study’s focus on demographic subset effects, particularly the emphasized risk profiles in males and younger patients, adds a critical layer of specificity that may guide future personalized medicine approaches. Biological sex and age-related differences in neuroendocrine and metabolic pathways could elucidate why these groups exhibit distinct vulnerability patterns, fostering tailored interventions that address these unique biochemical contexts.

As a retrospective observational analysis, the findings naturally prompt calls for longitudinal research to validate and expand upon these associations. Prospective studies could elucidate causal relationships, potentially establishing folate and homocysteine not only as markers but also as modifiable targets in suicide prevention strategies. Nutritional supplementation and metabolic modulation may emerge as adjunct therapeutic pathways, blending psychopharmacology with biochemical interventions.

The study also signifies the increasing utility of big data and electronic health records in psychiatric research, enabling nuanced phenotype classifications and biomarker analyses on unprecedented scales. Such technological integration promises enhanced diagnostic precision and the identification of biosignatures that transcend symptomatic assessments, ultimately transforming MDD management paradigms.

While the current research refrains from establishing definitive clinical protocols, it substantially advances the conceptual framework around suicidality biomarkers. It underscores the critical need for multidisciplinary approaches integrating psychiatry, biochemistry, and epidemiology to decode the complex etiologies underlying suicidal behavior and to craft effective prevention models.

In summary, the identification of serum folate and homocysteine as correlates of suicide risk within specific demographic groups of MDD patients offers an innovative frontier in psychiatric biomarker research. These findings carry the potential to transform suicide risk assessment from subjective narratives into measurable biological signals, opening avenues for early intervention and personalized care. As the psychiatric field grapples with the challenge of suicide prevention, such biomarker-driven insights are poised to pave the way for breakthroughs that could save countless lives worldwide.

Subject of Research: Biomarkers for suicide risk in major depressive disorder, focusing on serum folate and homocysteine levels and their associations particularly in males and younger patients.

Article Title: Serum folate and homocysteine as biomarkers for suicide risk in major depressive disorder: insights in males and younger patients

Article References:
Zhang, A., Qin, Y., Wang, H. et al. Serum folate and homocysteine as biomarkers for suicide risk in major depressive disorder: insights in males and younger patients. BMC Psychiatry 25, 745 (2025). https://doi.org/10.1186/s12888-025-07183-7

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12888-025-07183-7